ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)-Reference-Cited by-同舟云学术

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Published:2017-09 Issue:9 Volume:12 Page:1357-1367
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Cho Byoung Chul,Kim Dong-Wan,Bearz Alessandra,Laurie Scott A.,McKeage Mark,Borra Gloria,Park Keunchil,Kim Sang-We,Ghosn Marwan,Ardizzoni Andrea,Maiello Evaristo,Greystoke Alastair,Yu Richard,Osborne Karen,Gu Wen,Scott Jeffrey W.,Passos Vanessa Q.,Lau Yvonne Y.,Wrona Anna

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK;Shaw;J Clin Oncol,2009

3. US Food and Drug Administration. Ceritinib. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560873.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed May 27, 2017.

4. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial;Kim;Lancet Oncol,2016

5. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2;Crinò;J Clin Oncol,2016

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals;Current Problems in Cancer;2024-12

2. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

3. MC-Keyboard: A Practical Phase I Trial Design for Targeted Therapies and Immunotherapies Integrating Multiple-Grade Toxicities;Journal of Immunotherapy and Precision Oncology;2024-08-01

4. Ceritinib as a long-term disease control: Clinical observation;Meditsinskiy sovet = Medical Council;2024-07-24

5. Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens;Clinical Pharmacokinetics;2024-06